TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23311732
Drug: ACT-178882 300
Normalized name: ACT-541468
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACT-178882 300 mg single-dose
Study: 23311732
Drug: ACT-178882 300
Normalized name: ACT-541468
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACT-178882 300 or 600 mg multiple-dose
Study: 23311732
Drug: ACT-178882 multiple-dose
Normalized name: ACT-541468
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACT-178882 multiple-dose
Study: 21333466
Drug: Baclofen (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen (80 mg/day)
Study: 17643781
Drug: Photoprotection of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photoprotection of total parenteral nutrition (TPN)
Study: 17643781
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition (TPN) without photoprotection
Study: 15753144
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg RRR‐alpha‐tocopheryl acetate
Study: 15753144
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg all‐rac‐alpha‐tocopheryl acetate
Study: 11727359
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT) - 0.625 mg 17 beta‐estradiol plus 10 mg progestin, followed for 48 months
Study: 3367677
Drug: Low-energy helium-neon
Normalized name: neon
DrugBank: Neon (DB11589)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-energy helium-neon (HeNe) laser irradiation (0.9 mW) for 60 seconds daily over a 5-day period.
Study: 26440227
Drug: Ticagrelor 180
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 180 mg loading dose (LD)/90 mg twice‐daily maintenance dose (MD)
Study: 26440227
Drug: Clopidogrel 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 600 mg LD/75 mg once‐daily MD
Study: 9522323
Drug: 17 beta‐estradiol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 beta‐estradiol, 2 mg orally per day, continuously combined with dydrogesterone 2.5 mg
Study: 9522323
Drug: 17 beta‐estradiol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 beta‐estradiol, 2 mg orally per day, continuously combined with dydrogesterone 5 mg
Study: 9522323
Drug: 17 beta‐estradiol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 beta‐estradiol, 2 mg orally per day, continuously combined with dydrogesterone 10 mg
Study: 9522323
Drug: 17 beta‐estradiol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 beta‐estradiol, 2 mg orally per day, continuously combined with dydrogesterone 15 mg
Study: 29359385
Drug: Focused ultrasound
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focused ultrasound device (UltraShape) treatment on one thigh
Study: 12146536
Drug: Subantimicrobial dose
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subantimicrobial dose doxycycline (SDD)
Study: 17061750
Drug: Dietary soy
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary soy supplement
Study: 11205485
Drug: Dietary intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary intervention (ad libitum diet low in animal fat and refined carbohydrates, rich in low-glycemic-index foods, monounsaturated and n-3 polyunsaturated fatty acids, and phytoestrogens) with intensive dietary counseling and specially prepared group meals twice a week over 4.5 months.
Study: 7722994
Drug: Validated and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Validated and improved alcoholism treatment methods from Project MATCH and other studies
Study: 25722291
Drug: CC‐H5N1 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC‐H5N1 vaccine (3.75 µg of hemagglutinin antigen with AS03 adjuvant)
Study: 25722291
Drug: CC‐H5N1 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC‐H5N1 vaccine (1.9 µg of hemagglutinin antigen with AS03 adjuvant)
Study: 25722291
Drug: Embryonated-egg-derived vaccine
Normalized name: EGG
DrugBank: Egg (DB10529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Embryonated-egg-derived vaccine (3.75 µg of HA with AS03)
Study: 25722291
Drug: Embryonated-egg-derived vaccine
Normalized name: EGG
DrugBank: Egg (DB10529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Embryonated-egg-derived vaccine (15 µg of plain HA)
Study: 19016202
Drug: Intravenous moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous moxifloxacin plus intravitreal 1 mg Vancomycin plus 2.25 mg Ceftazidim
Study: 19016202
Drug: Intravenous moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous moxifloxacin only
Study: 12568412
Drug: Cal+D-group (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cal+D-group (1200 mg calcium plus 800 IU cholecalciferol)
Study: 12568412
Drug: Cal-group (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cal-group (1200 mg calcium)
Study: 10738705
Drug: Total dust
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total dust exposure (2.4 mg/m3)
Study: 10738705
Drug: Respirable dust
Approvals — FDA: no, EMA: no, PMDA: no
Description: Respirable dust exposure (0.16 mg/m3)
Study: 1405327
Drug: ANF (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANF (5 pmol/kg/min) with prazosin (0.25 mg)
Study: 1405327
Drug: Prazosin (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (0.25 mg)
Study: 29133954
Drug: Intravenous ghrelin
Normalized name: Ghrelin
DrugBank: Lenomorelin (DB11895)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ghrelin (3 mcg kg−1 loading dose followed by 16.9 ng/kg/min infusion)
Study: 29133954
Drug: Intravenous ghrelin
Normalized name: Ghrelin
DrugBank: Lenomorelin (DB11895)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ghrelin
Study: 21144850
Drug: Esomeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole (20 mg/day) + Clopidogrel (75 mg/day)
Study: 21144850
Drug: Clopidogrel alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel alone (75 mg/day)
Study: 3317340
Drug: Captopril (50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (50-100 mg/day)
Study: 3317340
Drug: Verapamil (160-240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (160-240 mg/day)
Study: 7027178
Drug: Acyclovir (ACV)
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acyclovir (ACV) 3% ointment
Study: 7027178
Drug: Idoxuridine (IDU)
Normalized name: Idoxuridine
DrugBank: Idoxuridine (DB00249)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Idoxuridine (IDU) 0.5% ointment
Study: 28070653
Drug: Phenylephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine infusion at 0.5 µg/kg/min during induction of anesthesia
Study: 28070653
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no phenylephrine infusion)
Study: 21992003
Drug: metoprolol 50
Normalized name: metoprolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoprolol 50 mg
Study: 21992003
Drug: metoprolol 25
Normalized name: metoprolol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoprolol 25 mg
Study: 3311661
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg cisapride administered tid for three days
Study: 3311661
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg cisapride administered tid for three days
Study: 26756988
Drug: Internet-administered questionnaires
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-administered questionnaires (SRS-30 and PODCI)
Study: 26756988
Drug: Pen and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pen and paper-administered questionnaires (SRS-30 and PODCI)
Study: 26756988
Drug: Paper-administered questionnaires
Normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paper-administered questionnaires (SRS-30 and PODCI)
Study: 21366030
Drug: Abdominal massage
Normalized name: PAD,ABDOMINAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abdominal massage with prescribed laxatives
Study: 21366030
Drug: Prescribed laxatives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescribed laxatives only
Study: 18651540
Drug: Ibandronate 2
Normalized name: ibandronate 2.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate 2 mg every 4 weeks for 48 weeks
Study: 19608831
Drug: Inhaled anesthetic
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled anesthetic technique using desflurane (DES)
Study: 15476159
Drug: 2-dose recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-dose recombinant HBV vaccination
Study: 15476159
Drug: 3-dose recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-dose recombinant HBV vaccination
Study: 15476159
Drug: 3-dose plasma-derived
Normalized name: c1-inhibitor, plasma derived
DrugBank: Human C1-esterase inhibitor (DB06404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-dose plasma-derived HBV vaccination
Study: 15476159
Drug: 3-dose regimens
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-dose regimens (both recombinant and plasma-derived)
Study: 11448901
Drug: Thalidomide (low-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide (low-dose arm, 200 mg/day)
Study: 11448901
Drug: Thalidomide (high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide (high-dose arm, escalated from 200 mg/day to 1200 mg/day)
Study: 9706917
Drug: HBOC‐201 (Study
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBOC‐201 (Study A: 6.9 mL/kg; Study B: 9.2 mL/kg)
Study: 2679035
Drug: Intravenous nicardipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nicardipine at an initial rate of 3 micrograms/kg/min
Study: 2679035
Drug: Intravenous nitroprusside
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nitroprusside at an initial rate of 1 microgram/kg/min
Study: 905083
Drug: Experimental group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group (treatment)
Study: 19726772
Drug: Fluvastatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin (80 mg extended-release once daily)
Study: 7880985
Drug: Sucralphate suspension
Normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucralphate suspension (1 g/5 ml)
Study: 7880985
Drug: Sucralphate tablet
Normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucralphate tablet (1 g)
Study: 2740067
Drug: Metoclopramide in
Normalized name: metoclopramide Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide in combination with low-dose chlorpromazine and high-dose hydrocortisone (regimen B)
Study: 31564831
Drug: IR‐ESO (esomeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: IR‐ESO (esomeprazole 20 mg/sodium bicarbonate 800 mg)
Study: 31564831
Drug: ESO (esomeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESO (esomeprazole 20 mg)
Study: 21224870
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (daily 2000 IU) for 10 weeks
Study: 21224870
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (daily 2000 IU)
Study: 21224870
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (daily 2000 IU) and Placebo
Study: 19882059
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose paracetamol (40 mg/kg orally)
Study: 11565628
Drug: Citalopram treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram treatment (n = 11) for 2 weeks
Study: 3162901
Drug: Intravenous enoxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous enoxacin 200 mg
Study: 3162901
Drug: Intravenous enoxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous enoxacin 800 mg
Study: 3162901
Drug: Oral enoxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral enoxacin 200 mg
Study: 3162901
Drug: Oral enoxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral enoxacin 800 mg
Study: 20978247
Drug: Neostigmine 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 50 μg/kg
Study: 17180485
Drug: Milk drink
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk drink supplemented with whey peptides (125 ml every morning for 12 weeks)
Study: 15539863
Drug: Rupatadine 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rupatadine 80 mg
Study: 3169959
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of zinc sulphate orally thrice a day for one month
Study: 21478756
Drug: Rabeprazole 0.14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 0.14 mg/kg (part 1)
Study: 21478756
Drug: Rabeprazole 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 0.5 mg/kg (part 2)
Study: 21478756
Drug: Rabeprazole 1
Normalized name: RABEprazole 10 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 1 mg/kg (part 2)
Study: 21478756
Drug: Rabeprazole (0.14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole (0.14 mg/kg, 0.5 mg/kg, 1 mg/kg)
Study: 15560155
Drug: Permixon (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Permixon (320 mg/day for 3, 6, and 12 months)
Study: 9070519
Drug: Desirudin (Revasc,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desirudin (Revasc, CGP 39393); 15 mg two times a day, administered subcutaneously for 8-11 days.
Study: 9070519
Drug: Unfractionated heparin;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unfractionated heparin; 5000 international units three times a day, administered subcutaneously for 8-11 days.
Study: 8379169
Drug: Cocktail-group received
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocktail-group received 100 ml of a homogenous fluorescein dilution
Study: 8379169
Drug: Fraction-group received
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fraction-group received 45 ml of unstained solution followed by 10 ml of concentrated dye
Study: 3723496
Drug: Nifedipine 10
Normalized name: nifedipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 10 mg TID
Study: 23327695
Drug: Large dose
Normalized name: Largemouth bass
DrugBank: Largemouth bass (DB10976)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large dose of continuous veno-venous hemodiafiltration (CVVHDF) (70 ml×kg(‐1)×h(‐1), n = 9)
Study: 23327695
Drug: Moderate dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate dose of CVVHDF (45 ml×kg(‐1)×h(‐1), n = 8)
Study: 23327695
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of CVVHDF (25 ml×kg(‐1)×h(‐1), n = 11)
Study: 20026597
Drug: 15 microg
Normalized name: Tafluprost 15 microgram/mL eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 microg dose of monovalent, unadjuvanted 2009 influenza A(H1N1) vaccine
Study: 20026597
Drug: 30 microg
Normalized name: Levonorgestrel 30 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 microg dose of monovalent, unadjuvanted 2009 influenza A(H1N1) vaccine
Study: 12945073
Drug: Intranasal mupirocin
Normalized name: Mupirocin
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal mupirocin (30 mg mupirocin calcium hydrate ointment topically to each nostril three times a day for 3 days before operation)
Study: 9368506
Drug: Pyridostigmine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine (60 mg orally every 6 h)
Study: 8248954
Drug: colestipol/niacin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: colestipol/niacin plus diet therapy
Study: 8248954
Drug: placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo plus diet therapy
Study: 27754722
Drug: Resveratrol (1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol (1,500 mg p.o. daily)
Study: 23014487
Drug: NaFeEDTA-fortified whole
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaFeEDTA-fortified whole wheat flour (6 mg of Fe)
Study: 18948800
Drug: Smoking cessation
Normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking cessation therapy with individual counseling and nicotine substitution starting 4 weeks before surgery and continuing 4 weeks postoperatively.
Study: 18948800
Drug: Smoking cessation
Normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking cessation therapy (abstainers).
Study: 15781813
Drug: Laquinimod 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laquinimod 0.3 mg
Study: 15781813
Drug: Laquinimod 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laquinimod 0.3 mg (subgroup with at least one active lesion at baseline)
Study: 9778752
Drug: Combined cold-adapted
Normalized name: COLD REMEDIES,COMBINATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined cold-adapted influenza A (H3N2) and trivalent inactivated influenza vaccine
Study: 7880088
Drug: Meningococcal A
Normalized name: MENINGOCOCCAL A/B/C/W/Y (PENBRAYA) KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meningococcal A and C polysaccharide vaccine
Study: 2008283
Drug: 2% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine with 0.06 meq/ml sodium bicarbonate (LPH)
Study: 24977996
Drug: 2% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine (L)
Study: 2008283
Drug: 2% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine with 1:100,000 epinephrine and 0.06 meq/ml sodium bicarbonate (LEPH)
Study: 205828
Drug: p-aminosalicylic acid
Normalized name: p-aminosalicylic acid
DrugBank: Aminosalicylic acid (DB00233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: p-aminosalicylic acid (PAS) 150 mg/kg/day
Study: 27651513
Drug: Simple Continuous
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple Continuous Infusion
Study: 27118470
Drug: Clopidogrel (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300 mg loading dose followed by 75 mg)
Study: 27118470
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (Aspirin 300 mg, Aspirin 75 mg, Clopidogrel)
Study: 9444449
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro in combination with NPH human insulin administered twice daily
Study: 9444449
Drug: Regular human
Normalized name: insulin regular human recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular human insulin in combination with NPH human insulin administered twice daily
Study: 7944443
Drug: Hepatectomy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatectomy and coagulation therapy for remaining tumor
Study: 7944443
Drug: Coagulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coagulation therapy only
Study: 3555566
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (verapamil 120 mg three times a day and atenolol 100 mg once a day)
Study: 3555566
Drug: Verapamil 120
Normalized name: verapamil 120 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 120 mg three times a day
Study: 386061
Drug: Atenolol 100
Normalized name: atenolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 100 mg once a day
Study: 26255172
Drug: Stepping Stones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepping Stones Triple P (SSTP) plus Acceptance and Commitment Therapy (ACT)
Study: 23954534
Drug: Steroids with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids with prompt delivery (PD group) after 48 hours
Study: 23954534
Drug: Steroids and
Normalized name: Corticosteroids and mydriatics in combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids and expectant management (EXM group)
Study: 23954534
Drug: Steroids with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids with prompt delivery (PD group)
Study: 18799288
Drug: d-cycloserine 50
Normalized name: D-(+)-cycloserine
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-cycloserine 50 mg once-weekly
Study: 28100438
Drug: 35 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 mg/kg rifampicin per day with isoniazid, pyrazinamide, and ethambutol
Study: 28100438
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg rifampicin per day with isoniazid, pyrazinamide, and SQ109
Study: 28100438
Drug: 20 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg rifampicin per day with isoniazid, pyrazinamide, and SQ109
Study: 28100438
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg rifampicin per day with isoniazid, pyrazinamide, and moxifloxacin
Study: 28100438
Drug: Control regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control regimen (10 mg/kg rifampicin, 5 mg/kg isoniazid, 25 mg/kg pyrazinamide, and 15-20 mg/kg ethambutol)
Study: 27208905
Drug: Subcutaneous trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous trastuzumab (600 mg fixed dose)
Study: 25403587
Drug: Intravenous trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous trastuzumab (weight-based)
Study: 25403587
Drug: Both subcutaneous
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both subcutaneous and intravenous trastuzumab
Study: 21813840
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of diethylcarbamazine and albendazole (DEC/ALB)
Study: 19076157
Drug: Melatonin 3
Normalized name: melatonin 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 3 mg at 22.00 h every night
Study: 15112170
Drug: N-acetylcysteine (NAC),
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC), 400 mg, thrice daily the day before and day of the contrast procedure
Study: 10782553
Drug: Coping-orientated group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coping-orientated group therapy
Study: 29725798
Drug: Supportive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive therapy group